Authorization Status and Update Nature

The European Medicines Agency (EMA) has reflected in its EPAR that Biogen Inc.'s (BIIB) Tecfidera (dimethyl fumarate) holds a valid marketing authorization in the European Union. The marketing authorization holder is Biogen Netherlands B.V., and it applies to adults and children aged 13 years and older with relapsing-remitting multiple sclerosis (RRMS). This action is a post-marketing regulatory process for managing the authorization, safety, and product information of an already marketed product, rather than a new approval or a recent clinical success. Therefore, it is more significant in ensuring the continued functioning of long-term prescription and pharmacovigilance systems than in serving as a catalyst for changing patient access.

Mechanism of Action and Clinical Evidence

Tecfidera is an oral immunomodulator, dimethyl fumarate, that activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, inducing antioxidant defense and anti-inflammatory responses. In a key clinical trial of 1,234 patients evaluated by the EMA, the proportion of patients with relapses within 2 years was 27% in the Tecfidera group and 46% in the placebo group. The current status is Marketed. Major risks include flushing, gastrointestinal disorders, lymphopenia, and progressive multifocal leukoencephalopathy (PML), with hematological monitoring being part of the product's value in long-term use. Its strength lies in being an established oral option, but the burden of safety management also determines its prescription competitiveness.

Global Regulatory History

The FDA approved Tecfidera for relapsing forms of multiple sclerosis on March 27, 2013, without a separate advisory committee (AdComm) vote, and the EU marketing authorization was granted on January 30, 2014. The positive opinion from the EMA's CHMP was adopted on March 21, 2013, and in Japan, it was approved on December 19, 2016, after PMDA review. Following the first PML case in 2014, the EMA initiated a risk review and in 2015 recommended strengthening the monitoring of lymphocyte counts and PML symptoms. This history demonstrates that maintaining the authorization is not simply a document renewal but a process of continuously integrating accumulated safety data into the product information.

Competition and Commercial Implications

The market for multiple sclerosis treatments in the seven major markets in 2025 is estimated at approximately USD 21.8 billion, but global Tecfidera sales have decreased from USD 232.8 million in 2024 to USD 168.2 million in 2025 due to the entry of multiple generics. Competitors include Ocrevus (ocrelizumab, CD20) from Roche (ROG.SW), Kesimpta (ofatumumab, CD20) from Novartis (NVS), Zeposia (ozanimod, S1P1/5) from Bristol Myers Squibb (BMY), and Aubagio (teriflunomide, DHODH) from Sanofi (SNY). Biogen is defending its franchise with Vumerity (diroximel fumarate, Nrf2 pathway), which has improved gastrointestinal tolerability, and sales of this product increased to USD 565.7 million in 2025. The EPAR update does not prevent generics, but it is a defensive lifecycle management (LCM) measure to maintain the safety data and prescription confidence of the original product.